{"schema_version":"secwatch.filing_event.v1","accession":"0000785161-22-000050","form_type":"8-K","ticker":"EHC","cik":"0000785161","company_name":"Encompass Health Corp","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.560469+00:00","generated_at":"2026-06-21T21:43:21.904749+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Encompass Health reaffirms FY2022 guidance at Mizuho CEO Insight Series","bullets":["Reiterates FY2022 net operating revenues guidance of $4.32B to $4.35B.","Reaffirms adjusted EBITDA guidance of $800M to $820M.","Reaffirms adjusted EPS from continuing ops guidance of $2.71 to $2.86.","CEO Mark Tarr participating in Mizuho CEO Insight Series on Nov 14, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000785161-22-000050","json":"https://secwatch.observer/filing/0000785161-22-000050.json","markdown":"https://secwatch.observer/filing/0000785161-22-000050.md","text":"https://secwatch.observer/filing/0000785161-22-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/785161/000078516122000050/0000785161-22-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/785161/000078516122000050/ehc-20221114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T21:43:21.904749+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}